Cansortium Future Growth
Future criteria checks 0/6
Cansortium's EPS is expected to grow by 137.5% per annum.
Key information
n/a
Earnings growth rate
137.5%
EPS growth rate
| Pharmaceuticals earnings growth | 23.8% |
| Revenue growth rate | n/a |
| Future return on equity | n/a |
| Analyst coverage | None |
| Last updated | n/a |
Recent future growth updates
Recent updates
Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 6/30/2024 | 103 | -13 | 8 | 15 | N/A |
| 3/31/2024 | 100 | -20 | 11 | 17 | N/A |
| 12/31/2023 | 97 | -23 | 12 | 18 | N/A |
| 9/30/2023 | 95 | -36 | 15 | 21 | N/A |
| 6/30/2023 | 92 | -36 | 12 | 19 | N/A |
| 3/31/2023 | 90 | -34 | 13 | 20 | N/A |
| 12/31/2022 | 88 | -37 | 12 | 19 | N/A |
| 9/30/2022 | 83 | -15 | 22 | 34 | N/A |
| 6/30/2022 | 76 | -2 | 7 | 24 | N/A |
| 3/31/2022 | 70 | -24 | -21 | 0 | N/A |
| 12/31/2021 | 65 | -19 | -26 | -5 | N/A |
| 9/30/2021 | 62 | -31 | -38 | -20 | N/A |
| 6/30/2021 | 61 | -47 | -26 | -15 | N/A |
| 3/31/2021 | 57 | -28 | -1 | 5 | N/A |
| 12/31/2020 | 52 | -37 | 1 | 7 | N/A |
| 9/30/2020 | 47 | -48 | 12 | 17 | N/A |
| 6/30/2020 | 40 | -51 | -5 | 2 | N/A |
| 3/31/2020 | 33 | -51 | -21 | -8 | N/A |
| 12/31/2019 | 29 | -53 | -37 | -23 | N/A |
| 9/30/2019 | 24 | -54 | -58 | -42 | N/A |
| 6/30/2019 | 19 | -13 | -46 | -29 | N/A |
| 3/31/2019 | 14 | -9 | -35 | -23 | N/A |
| 12/31/2018 | 8 | 0 | -22 | -12 | N/A |
| 9/30/2018 | 3 | 16 | -16 | -7 | N/A |
| 6/30/2018 | 0 | -15 | -13 | -8 | N/A |
| 3/31/2018 | 0 | -16 | N/A | -7 | N/A |
| 12/31/2017 | N/A | -10 | N/A | -5 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: Insufficient data to determine if CNTM.F's forecast earnings growth is above the savings rate (2.6%).
Earnings vs Market: Insufficient data to determine if CNTM.F's earnings are forecast to grow faster than the US market
High Growth Earnings: Insufficient data to determine if CNTM.F's earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: Insufficient data to determine if CNTM.F's revenue is forecast to grow faster than the US market.
High Growth Revenue: Insufficient data to determine if CNTM.F's revenue is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if CNTM.F's Return on Equity is forecast to be high in 3 years time